have no relationships relevant to the contents of this paper to disclose. At our site, we commonly use metoprolol for to treat atrial arrhythmias during pregnancy. Metoprolol is more effective in reducing the ventricular rate in AF/ AFL than labetalol (7) . Metoprolol can also be used while breastfeeding (6, 8) . Atenolol is an FDA class D medication and is often avoided because of its association with low birth weight. Calcium channel blockers can also be used to treat atrial arrhythmias.
Although not used in women in this study, oral verapamil is an FDA class C medication and can be effective in tachycardia management. Intravenous verapamil is often avoided because of the potential for maternal and neonatal hypotension. There are concerns related to teratogenicity with the use of diltiazem in animal studies at high doses, and therefore it is typically avoided in pregnancy when other options are available (9) . Digoxin is most often used in combination with other agents to control ventricular rate and is most effective at controlling ventricular response at rest (7, 10) . Digoxin, an FDA class C medication, has a long history of use in pregnancy (9) and has been used for the management of fetal arrhythmias (11) . Orally administered digoxin is excreted into breast milk at very low concentrations and is considered to be safe for use during lactation (12) . Although other antiarrhythmic drugs can be used to treat AF/AFL in women with heart disease, they are associated with potential serious adverse side effects, particularly the risk of proarrhythmia. The use of these antiarrhythmic medications needs to be individualized. Outside of pregnancy, amiodarone and sotalol are recommended for the treatment of atrial arrhythmias in patients with structural heart disease (13). Sotalol is an FDA class B medication and can be used to restore and maintain sinus rhythm, but therapy may be limited by fetal bradycardia (14) .
Sotalol results in maternal QT interval prolongation and potentially life-threatening arrhythmias and should only be used with close maternal monitoring (15) . Amiodarone is contraindicated during pregnancy because of its effect on the fetal thyroid function, but may be necessary in some patients with complex structural heart disease in whom other antiarrhythmic agents are ineffective or contraindicated (6, 16) . Amiodarone was used during pregnancy in 2 women with AF/AFL in this study.
Flecainide has been used to treat fetal arrhythmias, but fewer data are available on its safety for the treatment of maternal arrhythmias (17) . It is often avoided in women with structural heart disease (18).
For women presenting with new AF/AFL, cardioversion is often the treatment strategy of choice because rhythm control is preferred over rate control. In addition to maternal morbidity and mortality, the rates of fetal and neonatal complications in this study were also concerning (1). Low birth weight was more common in women with AF/AFL. There was also
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